KRAS and neuroblastoma: These findings demonstrate that SGSS05-NS3, a covalent SETD8 inhibitor impairs cell growth in both MYCN-WT and MYCN-amp NB cells, regardless MYCN status and without toxic effects in normal healthy cells.